First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension

European Respiratory Journal

Volumn 33, Issue 4, 2009, Pages 785-792

  Grimminger, F ^a   Weimann, G ^b   Frey, R ^b   Voswinckel, R ^a   Thamm, M ^a   Bolkow D ^a   Weissmann, N ^a   Muck W ^b   Unger, S ^c   Wensing, G ^b   Schermuly, R T ^a   Ghofrani, H A ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b Pharma Research Centre   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

Maximum tolerated dose; Pharmacokinetics; Phase ii clinical trial; Pulmonary hypertension; Soluble guanylyl cyclase; Vasodilation

Indexed keywords

BAY 632521; CALCIUM CHANNEL BLOCKING AGENT; GUANYLATE CYCLASE ACTIVATOR; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; RIOCIGUAT; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GAS EXCHANGE; HEART INDEX; HOT FLUSH; HUMAN; INHALATION; INTERSTITIAL LUNG DISEASE; LUNG EMBOLISM; LUNG FUNCTION; LUNG HEMODYNAMICS; MALE; MORNING DOSAGE; NOSE CONGESTION; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SINGLE DRUG DOSE; SYSTEMIC CIRCULATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; URINARY URGENCY; URINE RETENTION; VASODILATATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GUANYLATE CYCLASE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; OXIDATION-REDUCTION; PULMONARY CIRCULATION; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TREATMENT OUTCOME;

EID: 63849256355     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00039808     Document Type: Article

References (28)

1. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352: 719-725.
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
3. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
4. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-109.
5. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991; 100: 1268-1271.
6. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-3800.
7. Plastiras SC, Karadimitrakis SP, Kampolis C, Moutsopoulos HM, Tzelepis GE. Determinants of pulmonary arterial hypertension in scleroderma. Semin Arthritis Rheum 2007; 36: 392-396.
8. Billy-Brissac R, Blanchet-Deverly A, Etienne-Julan M, Foucan L. Pulmonary hypertension in an adult sickle cell population in Guadeloupe. lnt J Cardiol 2008; [Epub ahead of print PMID: 18466988].
9. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350: 886-895.
10. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114: 1417-1431.
11. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9269.
12. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 1977; 74: 3203-3207.
13. Naeije R, Huez S. Expert opinion on available options treating pulmonary arterial hypertension. Expert Opin Pharmacother 2007; 8: 2247-2265.
14. Atz AM, Adatia I, Wessel DL. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 1996; 62: 1759-1764.
15. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151: 384-389.
16. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006; 5: 689-702.
17. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136: 515-522.
18. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
19. Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003; 78: 1207-1213.
20. Schermuly R, Stasch JP, Pullamsetti SS, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008; 32: 881-891.
21. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900.
22. Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 2006; 129: 417-425.
23. Frey R, Muck W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Single-dose pharmacokinetics, tolerability and safety of the soluble guanylate cyclase stimulator BAY 63-2521; an ascending-dose study in healthy male volunteers. J Clin Pharmacol 2008; 48: 926-934.
24. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007; 30: 338-344.
25. Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004; 44: 1488-1496.
26. Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun 2005; 334: 930-938.
27. Michelakis ED. The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail Rev 2003; 8: 5-21.
28. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5: 755-768.